June 15, 2017 / 4:21 PM / 2 months ago

BRIEF-Eli Lilly files supplemental biologics license application with FDA for Taltz

June 15 (Reuters) - Eli Lilly And Co

* Eular 2017: Lilly's Taltz (ixekizumab) demonstrated significant improvements in disease signs and symptoms at 24 weeks among patients with active psoriatic arthritis who had prior inadequate response or intolerance to TNF inhibitors

* Eli Lilly and Co - Lilly has filed a supplemental biologics license application with FDA for Taltz as a treatment of adult patients with active PSA

* Eli Lilly - patients treated with either dosing regimen of Taltz experienced significant improvements compared with placebo in other key secondary measures

* Eli Lilly and Co - submissions to other regulatory agencies around world are expected later in the year for Taltz

* Eli Lilly and Co- serious adverse events and discontinuation rates due to adverse events were not significantly different between treatment groups

* Incidence of treatment-emergent adverse events was greater with Taltz treatment compared with placebo

* Taltz is also in Phase 3 trials for treatment of radiographic and non-radiographic axial spondyloarthritis Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below